1. Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. Daniels AB, Froehler MT, Pierce JM, Nunnally AH, Calcutt MW, Bridges TM, LaNeve DC, Williams PE, Boyd KL, Reyzer ML, Lindsley CW, Friedman DL, Richmond A (2018) Invest Ophthalmol Vis Sci 59(1): 446-454
    › Primary publication · 29368001 (PubMed) · PMC5783625 (PubMed Central)
  2. Engineered microfluidic bioreactor for examining the three-dimensional breast tumor microenvironment. Rogers M, Sobolik T, Schaffer DK, Samson PC, Johnson AC, Owens P, Codreanu SG, Sherrod SD, McLean JA, Wikswo JP, Richmond A (2018) Biomicrofluidics 12(3): 034102
    › Primary publication · 29774083 (PubMed) · PMC5938175 (PubMed Central)
  3. The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. Lavender N, Yang J, Chen SC, Sai J, Johnson CA, Owens P, Ayers GD, Richmond A (2017) BMC Cancer 17(1): 88
    › Primary publication · 28143493 (PubMed) · PMC5286656 (PubMed Central)
  4. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A (2017) Clin Cancer Res 23(13): 3371-3384
    › Primary publication · 28003307 (PubMed) · PMC5479746 (PubMed Central)
  5. MDM2 Antagonists Counteract Drug-Induced DNA Damage. Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A (2017) EBioMedicine : 43-55
    › Primary publication · 29030058 (PubMed) · PMC5652019 (PubMed Central)
  6. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Pellom ST, Dudimah DF, Thounaojam MC, Uzhachenko RV, Singhal A, Richmond A, Shanker A (2017) Oncotarget 8(5): 8604-8621
    › Primary publication · 28052005 (PubMed) · PMC5352426 (PubMed Central)
  7. Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma. Nichols EE, Richmond A, Daniels AB (2016) Semin Ophthalmol 31(4): 304-9
    › Primary publication · 27128983 (PubMed) · PMC5526754 (PubMed Central)
  8. The role of NF-kB in modulating antitumor immunity. Richmond A, Yang J (2016) Oncoimmunology 5(1): e1005522
    › Primary publication · 26942050 (PubMed) · PMC4760307 (PubMed Central)
  9. Study of Chemotaxis and Cell-Cell Interactions in Cancer with Microfluidic Devices. Sai J, Rogers M, Hockemeyer K, Wikswo JP, Richmond A (2016) Methods Enzymol : 19-45
    › Primary publication · 26921940 (PubMed) · PMC5378165 (PubMed Central)
  10. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM (2016) Nat Commun : 10582
    › Primary publication · 26822383 (PubMed) · PMC4740184 (PubMed Central)